To the issue of prevention of acute vessel optic neuropathy
DOI:
https://doi.org/10.31288/oftalmolzh201414447Keywords:
ischemic optic neuropathy, Lutein, ZeaxanthinAbstract
Vascular pathology of the eye is one of the leading causes of blindness. Diseases caused by circulatory disorders constitute 10—15 % of all eye diseases.
Purpose — to examine the preventive effect of lutein and zeaxanthin on the basis of clinical examination of patients with chronic vascular pathology. The possibility of acute vascular neuropathy for example, 57 patients (114 eyes) with chronic ischemic neuropathy of the optic nerve that within 3 months of receiving lutein and zeaxanthin, the control group consisted of 35 patients (70 eyes) who received no prophylactic treatment and in 3 patients (3 eyes) occurred venous occlusion and arterial occlusion of the vessels of the optic nerve.
Conclusions. Use of lutein and zeaxanthin is preventing the emergence and development of acute retinal vascular occlusion. Patients who did not receive prophylactic treatment (4,28 %). Getting the vascular occlusion optic nerve.
References
1.Alifanova TA, Alifanova TA, Zosimova YaO. The role of cardiovascular diseases in the formation of disabling ocular pathology. Proceedings of international scientific conference, dedicated to 100 anniversary of academician NA Pu-chkovskaya «Modern aspects of the clinic, diagnosis and treatment of eye dioseases». Odessa; 29- 30 May 2008.
2.Volosovets AP, Krivopustov SP, Morozov TS. Disturbance of microcirculation: relevance in pediatrics and prospects for treatment. Praktychna angiologiia. 2008;4:29-31. Russian.
3.Gromova OA, Kudrin AV. Neurochemistry of macro and microelements. New approaches to pharmacotherapy. M.; 2001. 272 p.
4.Guseva MP. «Lutein Complex for children» in eye diseases pediatric practice. Rossiiskaya pediatricheskaia oftalmologiia. 2007;1:9-14. Russian.
5.Zavgorodnya NG, Sarzhevska LE, Bezdenezhna OO, Bezugla OA, Zavgorodnya TS, Rudicheva OA. Eye ischemic syndrome, modern principles of diagnosis and treatment. Textbook. Zaporizhzhya. 2012. 248 p.
6.Kanski JJ. Diseases of the Ocular Fundus KaHCKii. Avetisov SE, editor. M.; 2008. 3153 p.
7.Libman ES, Shakhova YeV. Blindness and disability due to eye pathology in Russia. Vestn Oftalmol. 2006; 122(1): 33-40.
8.Morozov VI, Yakovlev AA. Pharmacotherapy of eye diseases. M.: Meditsina; 2004 512 p.
9.Nikiforov AS, Guseva MR. Neuroophthalmology. M.: GEOTAR-Media; 2008. 624 p.
10.Brown DM, Kaiser PK, Michels M. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;5:1432- 44.https://doi.org/10.1056/NEJMoa062655
11.Carneiro AM. Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab. Ophthalmologica. 2011;18:211-25.https://doi.org/10.1159/000323943
12.Gass JD. Stereoscopic Atlas of Macular Diseases: diagnosis and treatment. The C. V. Mosby Company. St.Louis.1987;1:69.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Н. В. Коновалова, Н. И. Нарицына, Т. М. Серебрина, А. Л. Резниченко
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
